Table 2.
Week | Treatment | Viable | Non-Viable | |||
---|---|---|---|---|---|---|
Zygote | DE | L1 | L2 | |||
0 | Control | 127 ± 11 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 ± 1 |
CR | 121 ± 9 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 ± 1 | |
TA | 119 ± 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 ± 1 | |
1 | Control | 34 ± 3 (29%) | 85 ± 13 (71%) | 0 (0%) | 0 (0%) | 6 ± 3 |
CR | 33 ± 3 (37%) | 55 ± 9 (63%) | 0 (0%) | 0 (0%) | 37 ± 8 | |
TA | 52 ± 5 (51%) | 49 ± 4 (49%) | 0 (0%) | 0 (0%) | 35 ± 5 | |
2 | Control | 7 ± 10 (7%) | 24 ± 4 (22%) | 77 ± 5 (70%) | 1 ± 2 (1%) | 12 ± 7 |
CR | 15 ± 4 (21%) | 21 ± 6 (29%) | 35 ± 8 (48%) | 1 ± 2 (2%) | 58 ± 24 | |
TA | 32 ± 5 (39%) | 34 ± 16 (40%) | 16 ± 1 (20%) | 1 ± 1 (1%) | 56 ± 18 | |
3 | Control | 2 ± 1 (2%) | 11 ± 3 (10%) | 32 ± 3 (29%) | 66 ± 5 (59%) | 25 ± 10 |
CR | 7 ± 4 (13%) | 11 ± 4 (20%) | 19 ± 5 (36%) | 17 ± 5 (31%) | 68 ± 13 | |
TA | 13 ± 3 (27%) | 14 ± 6 (28%) | 12 ± 3 (24%) | 10 ± 2 (21%) | 84 ± 7 | |
4 | Control | 1 ± 1 (0.5%) | 3 ± 2 (2%) | 13 ± 5 (12.5%) | 88 ± 4 (85%) | 28 ± 6 |
CR | 4 ± 1 (10) (10%) | 3 ± 2 (6%) | 10 ± 6 (25%) | 24 ± 2 (59%) | 77 ± 17 | |
TA | 4 ± 2 (12%) | 6 ± 1 (19%) | 10 ± 2 (30%) | 13 ± 1 (39%) | 84 ± 16 |